{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:41:59Z","timestamp":1782409319211,"version":"3.54.5"},"reference-count":116,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.autrev.2024.103668","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:16:30Z","timestamp":1729005390000},"page":"103668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of acute exacerbation in interstitial lung disease secondary to autoimmune rheumatic diseases: More questions than answers"],"prefix":"10.1016","volume":"23","author":[{"given":"Fabrizio","family":"Luppi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreina","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Faverio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Bendstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103668_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2072","article-title":"The diagnosis and management of interstitial lung diseases","volume":"350","author":"Wallis","year":"2015","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102451","article-title":"Interstitial pneumonia with autoimmune features: a single center prospective follow-up study","volume":"19","author":"Sebastiani","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"19","key":"10.1016\/j.autrev.2024.103668_bb0015","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jama.2024.3669","article-title":"Interstitial lung disease: a review","volume":"331","author":"Maher","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.autrev.2024.103668_bb0020","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"157","key":"10.1016\/j.autrev.2024.103668_bb0025","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0021-2020","article-title":"Lung complications of Sjogren syndrome","volume":"29","author":"Luppi","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.autrev.2024.103668_bb0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103668_bb0035","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41584-021-00721-z","article-title":"Acute exacerbation of interstitial lung disease associated with rheumatic disease","volume":"18","author":"Luppi","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103668_bb0045","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.rmed.2008.12.019","article-title":"Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases","volume":"103","author":"Suda","year":"2009","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103668_bb0050","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.21037\/jtd.2019.03.28","article-title":"Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature","volume":"11","author":"Manfredi","year":"2019","journal-title":"J Thorac Dis"},{"issue":"10","key":"10.1016\/j.autrev.2024.103668_bb0055","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.rmed.2006.02.002","article-title":"Acute exacerbation of interstitial pneumonia following surgical lung biopsy","volume":"100","author":"Kondoh","year":"2006","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103668_bb0060","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/crj.13304","article-title":"Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis","volume":"15","author":"Miyashita","year":"2021","journal-title":"Clin Respir J"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0065","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.pas.0000213341.70852.9d","article-title":"Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias","volume":"31","author":"Churg","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103668_bb0070","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11739-015-1204-x","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review","volume":"10","author":"Luppi","year":"2015","journal-title":"Intern Emerg Med"},{"issue":"7","key":"10.1016\/j.autrev.2024.103668_bb0075","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Acute exacerbations of idiopathic pulmonary fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103668_bb0080","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Spagnolo","year":"2022","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0085","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12890-021-01502-w","article-title":"A systematic review of the incidence, risk factors and prognosis of acute exacerbation of systemic autoimmune disease-associated interstitial lung disease","volume":"21","author":"Kamiya","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"8","key":"10.1016\/j.autrev.2024.103668_bb0090","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/resp.12862","article-title":"Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia","volume":"21","author":"Arai","year":"2016","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/j.autrev.2024.103668_bb0095","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.chest.2015.12.026","article-title":"Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening: a large cohort analysis","volume":"149","author":"Moua","year":"2016","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0100","article-title":"Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases","volume":"7","author":"Salonen","year":"2020","journal-title":"BMJ Open Respir Res"},{"issue":"5","key":"10.1016\/j.autrev.2024.103668_bb0105","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/resp.13682","article-title":"Acute exacerbations of fibrotic interstitial lung diseases","volume":"25","author":"Suzuki","year":"2020","journal-title":"Respirology"},{"issue":"9","key":"10.1016\/j.autrev.2024.103668_bb0110","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3390\/diagnostics11091623","article-title":"Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases","volume":"11","author":"Faverio","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.autrev.2024.103668_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/1479972318809476","article-title":"Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis","volume":"16","author":"Enomoto","year":"2019","journal-title":"Chron Respir Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12931-022-01978-y","article-title":"Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model","volume":"23","author":"Hozumi","year":"2022","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0125","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4103\/atm.atm_14_21","article-title":"Acute exacerbation in interstitial lung disease","volume":"16","author":"Alhamad","year":"2021","journal-title":"Ann Thorac Med"},{"issue":"9","key":"10.1016\/j.autrev.2024.103668_bb0130","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0135","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1183\/13993003.00419-2015","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm","volume":"46","author":"Ryerson","year":"2015","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.autrev.2024.103668_bb0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/resp.14643","article-title":"Pulse versus non-pulse corticosteroid therapy in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"29","author":"Hyung","year":"2024","journal-title":"Respirology"},{"key":"10.1016\/j.autrev.2024.103668_bb0145","doi-asserted-by":"crossref","DOI":"10.1111\/resp.14763","article-title":"Steroid therapy in acute exacerbation of fibrotic interstitial lung disease","author":"Koshy","year":"2024","journal-title":"Respirology"},{"key":"10.1016\/j.autrev.2024.103668_bb0150","doi-asserted-by":"crossref","DOI":"10.1177\/1479973119869334","article-title":"Acute exacerbations of idiopathic pulmonary fibrosis: does clinical stratification or steroid treatment matter?","volume":"16","author":"Cuerpo","year":"2019","journal-title":"Chron Respir Dis"},{"issue":"6","key":"10.1016\/j.autrev.2024.103668_bb0155","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/resp.13753","article-title":"Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF","volume":"25","author":"Farrand","year":"2020","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/j.autrev.2024.103668_bb0160","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1164\/ajrccm.185.5.587","article-title":"Steroids in idiopathic pulmonary fibrosis acute exacerbation: defenders or killers?","volume":"185","author":"Papiris","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0165","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.1038\/s41598-021-85539-1","article-title":"Corticosteroid responsiveness in patients with acute exacerbation of interstitial lung disease admitted to the emergency department","volume":"11","author":"Jang","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103668_bb0185","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103668_bb0190","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","article-title":"Scleroderma renal crisis: patient characteristics and long-term outcomes","volume":"100","author":"Penn","year":"2007","journal-title":"QJM"},{"issue":"9","key":"10.1016\/j.autrev.2024.103668_bb0195","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2024.103668_bb0200","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1620\/tjem.239.297","article-title":"High prevalence of acute exacerbation of interstitial lung disease in Japanese patients with systemic sclerosis","volume":"239","author":"Tomiyama","year":"2016","journal-title":"Tohoku J Exp Med"},{"issue":"21","key":"10.1016\/j.autrev.2024.103668_bb0205","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Idiopathic Pulmonary Fibrosis Clinical Research Network","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103668_bb0210","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01760-2019","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation","volume":"55","author":"Kreuter","year":"2020","journal-title":"Eur Respir J"},{"issue":"Suppl. 5","key":"10.1016\/j.autrev.2024.103668_bb0215","first-page":"v1","article-title":"Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society","volume":"63","author":"Bradley","year":"2008","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.autrev.2024.103668_bb0220","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4046\/trd.2019.0009","article-title":"Korean guidelines for diagnosis and management of interstitial lung diseases: part 5. Connective tissue disease associated interstitial lung disease","volume":"82","author":"Koo","year":"2019","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0225","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2213-2600(21)00354-4","article-title":"Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"10","author":"Naccache","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103668_bb0230","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccm.2019.05.001","article-title":"Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease","volume":"40","author":"Perelas","year":"2019","journal-title":"Clin Chest Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0235","article-title":"Cyclophosphamide for the treatment of acute exacerbation of interstitial lung disease: a review of the literature","volume":"38","author":"Innabi","year":"2021","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"11","key":"10.1016\/j.autrev.2024.103668_bb0240","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103668_bb0245","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/BOR.0000000000000270","article-title":"Management of connective tissue diseases associated interstitial lung disease: a review of the published literature","volume":"28","author":"Wallace","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103668_bb0250","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.semarthrit.2021.07.008","article-title":"Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: a propensity-matched analysis using a nationwide inpatient database","volume":"51","author":"Nakamura","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"3\u20134","key":"10.1016\/j.autrev.2024.103668_bb0255","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2152\/jmi.63.294","article-title":"Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease","volume":"63","author":"Toyoda","year":"2016","journal-title":"J Med Invest"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/14397595.2016.1173816","article-title":"Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease","volume":"27","author":"Ota","year":"2017","journal-title":"Mod Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2024.103668_bb0265","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1164\/rccm.201203-0506OC","article-title":"Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses","volume":"187","author":"Kahloon","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103668_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127771","article-title":"Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis","volume":"10","author":"Donahoe","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2024.103668_bb0275","author":"Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF). ID: NCT03286556"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0280","first-page":"95","article-title":"Rituximab for salvage therapy of refractory hypersensitivity pneumonitis","volume":"118","author":"Tamm","year":"2019","journal-title":"WMJ"},{"issue":"30","key":"10.1016\/j.autrev.2024.103668_bb0285","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021473","article-title":"Acute severe idiopathic lymphoid interstitial pneumonia: a case report","volume":"99","author":"Lamkouan","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0290","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000430100","article-title":"Successful rituximab therapy in steroid-resistant, cryptogenic organizing pneumonia: a case series","volume":"90","author":"Shitenberg","year":"2015","journal-title":"Respiration"},{"issue":"3","key":"10.1016\/j.autrev.2024.103668_bb0295","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003479","article-title":"Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease","volume":"9","author":"Le\u00f3n Rom\u00e1n","year":"2023","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.autrev.2024.103668_bb0300","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MCP.0b013e3283567ff9","article-title":"The big clinical trials in idiopathic pulmonary fibrosis","volume":"18","author":"Luppi","year":"2012","journal-title":"Curr Opin Pulm Med"},{"issue":"12","key":"10.1016\/j.autrev.2024.103668_bb0305","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.autrev.2024.103668_bb0310","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0315","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","article-title":"Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS","volume":"193","author":"Costabel","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2024.103668_bb0320","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(\u00ae) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"issue":"150","key":"10.1016\/j.autrev.2024.103668_bb0325","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0071-2018","article-title":"Acute exacerbations of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Kolb","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"9","key":"10.1016\/j.autrev.2024.103668_bb0330","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103668_bb0335","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"issue":"22","key":"10.1016\/j.autrev.2024.103668_bb0340","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"9779","key":"10.1016\/j.autrev.2024.103668_bb0345","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.autrev.2024.103668_bb0350","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","article-title":"Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.autrev.2024.103668_bb0355","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00595-014-1071-5","article-title":"Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis","volume":"45","author":"Iwata","year":"2015","journal-title":"Surg Today"},{"key":"10.1016\/j.autrev.2024.103668_bb0360","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.rmed.2017.03.026","article-title":"Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study","volume":"126","author":"Furuya","year":"2017","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.autrev.2024.103668_bb0365","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1159\/000509556","article-title":"Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers","volume":"99","author":"Faverio","year":"2020","journal-title":"Respiration"},{"issue":"18","key":"10.1016\/j.autrev.2024.103668_bb0370","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103668_bb0375","first-page":"317","article-title":"Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases","volume":"26","author":"Ito","year":"2019","journal-title":"Respir Med Case Rep"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.215","article-title":"Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis","volume":"5","author":"Tomioka","year":"2017","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.autrev.2024.103668_bb0385","article-title":"Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases","volume":"33","author":"Nakashima","year":"2021","journal-title":"Respir Med Case Rep"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0390","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.resinv.2014.09.003","article-title":"Efficacy of combined corticosteroid and pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis after surgery for lung cancer: a case report","volume":"53","author":"Ohkubo","year":"2015","journal-title":"Respir Investig"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0395","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis with Pirfenidone and nintedanib: a friend or foe","volume":"14","author":"Kaushal","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0400","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00281-011-0282-8","article-title":"Thrombomodulin and its role in inflammation","volume":"34","author":"Conway","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103668_bb0405","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000369828","article-title":"Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study","volume":"89","author":"Isshiki","year":"2015","journal-title":"Respiration"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0410","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1378\/chest.14-2746","article-title":"Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis","volume":"148","author":"Kataoka","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2024.103668_bb0415","first-page":"5755","article-title":"Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study","volume":"9","author":"Abe","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0420","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3892\/etm.2020.8709","article-title":"Efficacy of recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"20","author":"Wang","year":"2020","journal-title":"Exp Ther Med"},{"issue":"9","key":"10.1016\/j.autrev.2024.103668_bb0425","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1164\/rccm.201909-1818OC","article-title":"Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis. A randomized, double-blind placebo-controlled trial","volume":"201","author":"Kondoh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103668_bb0430","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1440-1843.2008.01290.x","article-title":"Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia","volume":"13","author":"Enomoto","year":"2008","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0435","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1046\/j.1526-0968.2003.00005.x","article-title":"Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin)","volume":"7","author":"Shoji","year":"2003","journal-title":"Ther Apher Dial"},{"issue":"2","key":"10.1016\/j.autrev.2024.103668_bb0440","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000510290","article-title":"Cytokine adsorption to polymyxin B-immobilized fiber: an in vitro study","volume":"50","author":"Utsunomiya","year":"2021","journal-title":"Blood Purif"},{"issue":"15","key":"10.1016\/j.autrev.2024.103668_bb0445","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12890-015-0004-4","article-title":"Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival","volume":"22","author":"Enomoto","year":"2015","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0450","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40981-022-00589-2","article-title":"Hemodiafiltration combined with polymyxin B-immobilized fiber column direct hemoperfusion is effective for acute postoperative exacerbation of interstitial pneumonia: a case report","volume":"8","author":"Yokoyama","year":"2022","journal-title":"JA Clin Rep"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0455","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s12890-022-02197-3","article-title":"Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases","volume":"22","author":"Enomoto","year":"2022","journal-title":"BMC Pulm Med"},{"issue":"7","key":"10.1016\/j.autrev.2024.103668_bb0460","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/resp.13054","article-title":"Direct hemoperfusion with polymyxin B-immobilized fibre treatment for acute exacerbation of interstitial pneumonia","volume":"22","author":"Furusawa","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.autrev.2024.103668_bb0465","doi-asserted-by":"crossref","DOI":"10.1177\/2050312119861821","article-title":"A systematic review of the efficacy of direct hemoperfusion with a polymyxin B-immobilized fibre column to treat rapidly progressive interstitial pneumonia","volume":"7","author":"Kamiya","year":"2019","journal-title":"SAGE Open Med"},{"issue":"7","key":"10.1016\/j.autrev.2024.103668_bb0470","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1753465817708950","article-title":"Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies","volume":"11","author":"Ichiyasu","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.autrev.2024.103668_bb0475","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12890-015-0066-3","article-title":"Role of bronchoalveolar lavage in the diagnosis of acute exacerbations of idiopathic pulmonary fibrosis: a retrospective study","volume":"15","author":"Petrosyan","year":"2015","journal-title":"BMC Pulm Med"},{"issue":"7","key":"10.1016\/j.autrev.2024.103668_bb0480","doi-asserted-by":"crossref","first-page":"903","DOI":"10.7150\/ijms.4972","article-title":"Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis","volume":"10","author":"Ding","year":"2013","journal-title":"Int J Med Sci"},{"issue":"8","key":"10.1016\/j.autrev.2024.103668_bb0485","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/1744666X.2020.1803064","article-title":"Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia","volume":"16","author":"Manfredi","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0490","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-020-01459-0","article-title":"The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease","volume":"21","author":"Hoffmann-Vold","year":"2020","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.autrev.2024.103668_bb0495","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","article-title":"Palliative care in interstitial lung disease: living well","volume":"5","author":"Kreuter","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103668_bb0500","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/17476348.2018.1446831","article-title":"Treatment of acute exacerbations of interstitial lung disease","volume":"12","author":"Azadeh","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.autrev.2024.103668_bb0505","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620906327","article-title":"Pulse oximetric saturation to fraction of inspired oxygen (SpO2\/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease","volume":"14","author":"Koyauchi","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.autrev.2024.103668_bb0510","doi-asserted-by":"crossref","first-page":"30629","DOI":"10.3402\/ecrj.v3.30629","article-title":"Opioids: an unexplored option for treatment of dyspnea in IPF","volume":"3","author":"Kohberg","year":"2016","journal-title":"Eur Clin Respir J"},{"issue":"10","key":"10.1016\/j.autrev.2024.103668_bb0515","article-title":"Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults","volume":"10","author":"Simon","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.autrev.2024.103668_bb0520","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01278-2018","article-title":"Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study","volume":"52","author":"Bajwah","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0525","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12931-020-01452-7","article-title":"Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease - a randomised placebo-controlled trial","volume":"21","author":"Kronborg-White","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.autrev.2024.103668_bb0530","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1177\/10499091241227556","article-title":"Perceptions on use of opioids in palliative care of dyspnoea in patients with fibrotic interstitial lung disease and chronic obstructive pulmonary disease: a qualitative study","volume":"41","author":"Hvelplund","year":"2024","journal-title":"Am J Hosp Palliat Care"},{"issue":"147","key":"10.1016\/j.autrev.2024.103668_bb0535","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2017","article-title":"Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions","volume":"27","author":"Ferrara","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.autrev.2024.103668_bb0540","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S2213-2600(23)00432-0","article-title":"Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial","volume":"12","author":"Wu","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"145","key":"10.1016\/j.autrev.2024.103668_bb0545","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0050-2017","article-title":"Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis","volume":"26","author":"Kondoh","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"5","key":"10.1016\/j.autrev.2024.103668_bb0550","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","article-title":"Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials","volume":"1","author":"Lee","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.autrev.2024.103668_bb0555","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/resp.14788","article-title":"Treatment of acute exacerbations of interstitial lung diseases with corticosteroids: evidence?","volume":"29","author":"Hung","year":"2024","journal-title":"Respirology"},{"key":"10.1016\/j.autrev.2024.103668_bb0560","author":"EXAFIP2. ID: NCT05674994"},{"key":"10.1016\/j.autrev.2024.103668_bb0565","author":"Efficacy of Steroid Pulse Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF) Admitted in ER. ID: NCT04996303"},{"issue":"4","key":"10.1016\/j.autrev.2024.103668_bb0570","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/jcm9041082","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103668_bb0575","first-page":"542","article-title":"Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients","volume":"35","author":"Sebastiani","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103668_bb0580","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.tips.2018.11.002","article-title":"Non-genomic effects of glucocorticoids: an updated view","volume":"40","author":"Panettieri","year":"2019","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2024.103668_bb0585","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.resinv.2018.06.002","article-title":"Ethnic differences in idiopathic pulmonary fibrosis: the Japanese perspective","volume":"56","author":"Saito","year":"2018","journal-title":"Respir Investig"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T03:13:19Z","timestamp":1732677199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224001599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":116,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1568997224001599"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103668","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of acute exacerbation in interstitial lung disease secondary to autoimmune rheumatic diseases: More questions than answers","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103668"}}